Fig. 5.
Line graphs illustrate the concentration-dependent effects of 2′,3′-cAMP on [3H]thymidine incorporation (A) and cell number (B) in rat AVSMCs. Bar graph (C) illustrates effects of 1,3-dipropyl-8-cyclopentylxanthine [DPCPX (A1 antagonist)], 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine [SCH-58261 (A2A antagonist)], 8-(4-{[(4-cyanophenyl)carbamoylmethyl]oxy}phenyl)-1,3-di(n-propyl)xanthine [MRS-1754 (A2B antagonist)], and N-(2-methoxyphenyl)-N′-[2-(3-pyridinyl)-4-quinazolinyl]-urea [VUF-5574 (A3 antagonist)] (each at 0.1 μmol/l) on inhibition of [3H]thymidine incorporation by 2′,3′-cAMP (30 μmol/l) in rat AVSMCs. P values are from 1-factor ANOVA. aP < 0.05 [Fisher's least-significant difference (LSD) test] compared with basal (0) (A and B) or compared with no inhibitor (C).